Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bauersachs

Showing results (31-40 of 132) with videos related to

Pageof 14
Sort By:
Research and Practice in Thrombosis and Haemostasis|June 18, 2020
Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxabanRupert Bauersachs, Alok A Khorana, Agnes Y Y Lee, et al.
MMW Fortschritte Der Medizin|March 1, 2017
[Perioperative anticoagulation with NOAC using the example of rivaroxaban]Jürgen Koscielny, Christian von Heymann, Rupert Bauersachs, et al.
British Journal of Haematology|August 30, 2002
Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparinEdelgard Lindhoff-Last, Roumen Nakov, Frank Misselwitz, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 15, 2017
Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-AnalysisM José Martínez-Zapata, Alexander G Mathioudakis, Shaker A Mousa, et al.
Journal of Thrombosis and Thrombolysis|August 12, 2015
Preferences for anticoagulation therapy in atrial fibrillation: the patients' viewBjörn Böttger, Inga-Marion Thate-Waschke, Rupert Bauersachs, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 9, 2003
Risk factors and long-term follow-up of patients with the immune type of heparin-induced thrombocytopeniaEdelgard Lindhoff-Last, Britta Wenning, Martina Stein, et al.
Clinical Pharmacology and Therapeutics|March 7, 2003
Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular diseaseUte Klinkhardt, Rupert Bauersachs, Jan Adams, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|July 17, 2018
Sex hormones and venous thromboembolism - from contraception to hormone replacement therapyJan Beyer-Westendorf, Rupert Bauersachs, Viola Hach-Wunderle, et al.
Deutsche Medizinische Wochenschrift (1946)|May 15, 2019
[Anti-Thrombotic Therapy of Peripheral Arterial Disease - A Review of Current Evidence, Practice and Outlook]Rupert Bauersachs, Christine Espinola-Klein, Holger Lawall, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 18, 2002
MIXCON-LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulantEdelgard Lindhoff-Last, Marek Humpich, Jörn Schmitt, et al.
Pageof 14

Showing results (31-40 of 132) with videos related to

Sort By:
Pageof 14
Research and Practice in Thrombosis and Haemostasis|June 18, 2020
Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxabanRupert Bauersachs, Alok A Khorana, Agnes Y Y Lee, et al.
MMW Fortschritte Der Medizin|March 1, 2017
[Perioperative anticoagulation with NOAC using the example of rivaroxaban]Jürgen Koscielny, Christian von Heymann, Rupert Bauersachs, et al.
British Journal of Haematology|August 30, 2002
Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparinEdelgard Lindhoff-Last, Roumen Nakov, Frank Misselwitz, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 15, 2017
Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-AnalysisM José Martínez-Zapata, Alexander G Mathioudakis, Shaker A Mousa, et al.
Journal of Thrombosis and Thrombolysis|August 12, 2015
Preferences for anticoagulation therapy in atrial fibrillation: the patients' viewBjörn Böttger, Inga-Marion Thate-Waschke, Rupert Bauersachs, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 9, 2003
Risk factors and long-term follow-up of patients with the immune type of heparin-induced thrombocytopeniaEdelgard Lindhoff-Last, Britta Wenning, Martina Stein, et al.
Clinical Pharmacology and Therapeutics|March 7, 2003
Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular diseaseUte Klinkhardt, Rupert Bauersachs, Jan Adams, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|July 17, 2018
Sex hormones and venous thromboembolism - from contraception to hormone replacement therapyJan Beyer-Westendorf, Rupert Bauersachs, Viola Hach-Wunderle, et al.
Deutsche Medizinische Wochenschrift (1946)|May 15, 2019
[Anti-Thrombotic Therapy of Peripheral Arterial Disease - A Review of Current Evidence, Practice and Outlook]Rupert Bauersachs, Christine Espinola-Klein, Holger Lawall, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 18, 2002
MIXCON-LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulantEdelgard Lindhoff-Last, Marek Humpich, Jörn Schmitt, et al.
Pageof 14